A potential cancer drug aimed at enhancing the effectiveness of ionizing radiation in lung cancer patients is a step closer to development with funding support from the Small Business Innovation Research (SBIR) program.

The T.J. Martell Foundation’s 6th Annual Chic Awearness fundraising event that supports ovarian cancer research at Vanderbilt-Ingram Cancer Center will be held Monday, Sept. 24, 6:30 – 8:30 p.m.

Vanderbilt researchers have identified a new vulnerability in lung cancer — the transporter protein xCT — that may a therapeutic target for the disease.

A receptor previously implicated in asthma may also play roles in other allergic diseases and in leukemia, Vanderbilt researchers have discovered.

Loss of a gene that is part of the TGF-beta signaling pathway increased inflammation in the colon and was observed in half of human colitis-associated cancers.

Jun. 28, 2018—An international coalition led by scientists at Vanderbilt University Medical Center and the QIMR Berghofer Medical Research Institute in Herston, Australia, has identified 48 candidate susceptibility genes for breast cancer risk, including 14 genes at loci (chromosome regions) not yet reported for breast cancer.

A group of young lung cancer patients and their family members recently toured research laboratories at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center (VICC) to learn how investigators are working to find better therapies and possibly a cure for the disease.